1. National Institutes of Health, Office of Biotechnology Activities. Clinical Trials in Human Gene Transfer-Recom-binant and Gene Transfer, 2002, http://www4.od.nih.gov/oba/rac/clinicaltrial.htm.
2. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048-3057.
3. Verhasselt B, De Smedt M, Verhelst R, Naessens E, Plum J. Retrovirally transduced CD34++ human cord blood cells generate T cells expressing high levels of the retroviral encoded green fluorescent protein marker in vitro. Blood 1998;91:431-440.
4. Stewart AK, Sutherland DR, Nanji S, et al. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures. Hum Gene Ther 1999;10:1953-1964.
5. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
6. Sharma S, Cantwell M, Kipps TJ, Friedmann T. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci USA 1996;93:11,842-11,847.
7. Lukashok SA, Horwitz MS. New perspectives in adenoviruses. Curr Clin Top Infect Dis 1998;18:286-305.
8. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999;886:158-171.
9. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepato-cytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994;1:433-442.
10. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995;155:2564-2570.
11. Borgland SL, Bowen GP, Wong NC, Libermann TA, Muruve DA. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 2000;74:3941-3947.
12. Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood 1996;88:4676-4683.
13. McDonald D, Stockwin L, Matzow T, Blair Zajdel ME, Blair GE. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther 1999;6:1512-1519.
14. Santis G, Legrand V, Hong SS, et al. Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol 1999;80:1519-1527.
15. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999;103:579-587.
16. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999;35:867-885.
17. Kouraklis G. Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 2000;45:1045-1052.
18. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
19. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568-8577.
20. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999;73:5438-5447.
21. Miao CH, Snyder RO, Schowalter DB, et al. The kinetics of rAAV integration in the liver. Nat Genet 1998;19:13-15.
22. Russell DW, Kay MA. Adeno-associated virus vectors and hematology. Blood 1999;94:864-874.
23. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000;6:433-440.
24. Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci 2000;7:279-291.
25. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999;10:1031-1039.
26. Omori F, Messner HA, Ye C, et al. Nontargeted stable integration of recombinant adeno-associated virus into human leukemia and lymphoma cell lines as evaluated by fluorescence in situ hybridization. Hum Gene Ther 1999; 10:537-543.
27. Krisky DM, Marconi PC, Oligino TJ, et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 1998;5:1517-1530.
28. Wolfe D, Goins WF, Kaplan TJ, et al. Herpesvirus-mediated systemic delivery of nerve growth factor. Mol Ther 2001;3:61-69.
29. Eling DJ, Johnson PA, Sharma S, Tufaro F, Kipps TJ. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther 2000;7:1210-1216.
30. Frenkel N, Singer O, Kwong AD. Minireview: the herpes simplex virus amplicon—a versatile defective virus vector. Gene Ther 1994;1:S40-46.
31. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982;30:295-304.
32. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996;70:7190-7197.
33. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998;72:7137-7143.
34. Saeki Y, Ichikawa T, Saeki A, et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998;9:2787-2794.
35. Tolba KA, Bowers WJ, Hilchey SP, et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 2001;98:287-295.
36. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther 2000;2:302-317.
37. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 1991; 266:19867-19870.
38. Zhu D, Rice J, Savelyeva N, Stevenson FK. DNA fusion vaccines against B-cell tumors. Trends Mol Med 2001; 7:566-572.
39. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 2001;167:1558-1565.
40. Stevenson FK, Rosenberg W. DNA vaccination: a potential weapon against infection and cancer. Vox Sang 2001; 80:12-18.
41. Uchida E, Mizuguchi H, Ishii-Watabe A, Hayakawa T. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002;25:891-897.
42. Dalpke AH, Zimmermann S, Albrecht I, Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002;106:102-112.
43. Yuen AR, Sikic BI. Clinical studies of antisense therapy in cancer. Front Biosci 2000;5:D588-593.
44. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
45. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000;68:455-463.
46. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000;28:558-568.
47. Castro JE, Motta M, Kipps TJ. The level of cell surface expression of TLR-9 does not correlate with the degree of activation mediated by immunostimulatory DNA sequences in patients with B cell CLL. In: Proceedings of the American Society of Hematology Annual Meeting, Orlando, FL, 2001, abstract 643.
48. Marschitz I, Tinhofer I, Hittmair A, et al. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol 2000;113:219-229.
49. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:611-615.
50. Klein A, Miera O, Bauer O, Golfier S, Schriever F. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000;14:40-46.
51. Stoetzer OJ, Pogrebniak A, Scholz M, et al. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia 1999;13:1873-1880.
52. Pepper C, Hooper K, Thomas A, Hoy T, Bentley P. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 2001;42:491-498.
53. O'Brien S, et al. Bcl-2 antisense (Genasense) as monotherepy for refractory chronic lymphocytic leukemia. In: Proceeding of the American Society of Hematology Annual Meeting, Orlando, FL, 2001.
54. Bubenik J, Zeuthen J, Bubenikova D, Simova J, Jandlova T. Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets. Anticancer Res 1993;13:1457-1460.
55. Simova J, Bubenik J, Jandlova T, Indrova M. Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines. Int J Oncol 1998;12:1195-1198.
56. Takahashi S, Rousseau RF, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 2001;12: 659-670.
57. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998;101:1133-1141.
58. Nishimura T, Watanabe K, Yahata T, et al. The application of IL-12 to cytokine therapy and gene therapy for tumors. Ann NY Acad Sci 1996;795:375-378.
59. Fernandez NC, Levraud JP, Haddada H, Perricaudet M, Kourilsky P. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 1999;162:609-617.
60. Aguilar-Santelises M, Gigliotti D, Osorio LM, et al. Cytokine expression in B-CLL in relation to disease progression and in vitro activation. Med Oncol 1999;16:289-295.
61. Gautam SC, Pindolia KR, Xu YX, et al. Antileukemic activity of TNF-alpha gene therapy with myeloid progenitor cells against minimal leukemia. J Hematother 1998;7:115-125.
62. Gautam SC, Xu YX, Pindolia KR, et al. TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy. J Hematother 1999;8:237-245.
63. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 1995;161:226-235.
64. Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 2000;6:81-87.
65. Sivaraman S, Deshpande CG, Ranganathan R, et al. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha? Microsc Res Tech 2000;50:251-257.
66. Villani F, Galimberti M, Mazzola G, et al. Pulmonary toxicity of alpha tumor necrosis factor in patients treated by isolation perfusion. J Chemother 1995;7:452-454.
67. Krigel RL, Padavic-Shaller KA, Rudolph AA, et al. Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor. J Natl Cancer Inst 1991;83:129-131.
68. Kuei JH, Tashkin DP, Figlin RA. Pulmonary toxicity of recombinant human tumor necrosis factor. Chest 1989;96: 334-338.
69. Marr RA, Addison CL, Snider D, et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-mutant of murine TNF alpha. Gene Ther 1997;4:1181-1188.
70. Marr RA, Hitt M, Gauldie J, Muller WJ, Graham FL. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Ther 1999;6:465-474.
71. Cantwell M, Kipps TJ. Infection of CLL using chimeric construcs of TNF. In: Proceedings of the IWCLL, San Diego, CA, 2002.
72. Hirano N, Takahashi T, Ohtake S, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-1176.
73. Cantwell MJ, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Med 1997;3:984-989.
74. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-935.
75. Van Kooten C, Banchereau J, CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61:1-77.
76. Lanier LL, O'Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995;154:97-105.
77. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996;156:1126-1131.
78. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-2924.
Clinical Aspects: Complications
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.